Elucidating the cardioprotective mechanisms of sodium-glucose cotransporter-2 inhibitors beyond glycemic control

doi:10.4239/wjd.v15.i2.137

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2723)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

WORD

HTML

1475

Figures (1-1)

209

Sum=1783

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

254

Download

505

Sum=759

Feb 15, 2024 (publication date) through Nov 29, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Diabetes. Feb 15, 2024; 15(2): 137-141
Published online Feb 15, 2024. doi: 10.4239/wjd.v15.i2.137

Full Size Figure Download Figure

Figure 1 The cardioprotective mechanisms of sodium-glucose cotransporter-2 inhibitors beyond glycemic control. SGLT2i: Sodium-glucose cotransporter-2 inhibitor; AMPK: Adenosine monophosphate-activated protein kinase; Akt: Protein kinase B; eNOS: Endothelial nitric oxide synthase; NO: Nitric oxide; PGC-1α: Peroxisome proliferator-activated receptor gamma coactivator-1alpha; ULK1: Unc-51 like autophagy activating kinase 1; FUNDC1: FUN14 domain containing 1.

Citation: Zhang KX, Kan CX, Han F, Zhang JW, Sun XD. Elucidating the cardioprotective mechanisms of sodium-glucose cotransporter-2 inhibitors beyond glycemic control. World J Diabetes 2024; 15(2): 137-141
URL: https://www.wjgnet.com/1948-9358/full/v15/i2/137.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i2.137